Trusts can take cost into account when deciding drug treatmentBMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7547.928-a (Published 20 April 2006) Cite this as: BMJ 2006;332:928
- Clare Dyer, legal correspondent
Last week's Appeal Court judgment to force the NHS to pay for trastuzumab (Herceptin) will not oblige primary care trusts to fund the drug for every woman whose oncologist prescribes it—although most of the media reported that it would.
Three Appeal Court judges headed by the master of the rolls, Anthony Clarke, unanimously ruled that Swindon NHS Primary Care Trust irrationally and unlawfully refused to pay for the treatment for Ann Marie Rogers, 54, who has early stage HER2 positive breast cancer.
The drug has been licensed and assessed …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial